Propanc Biopharma, Inc.

CAMBERWELL, VIC, C3 · Founded 2010 · Biotech · Public

Pancreatic proenzyme formulation to suppress tumor recurrence and metastasis

Claim this profile

Follows are private to you and power your alerts

Updated · propanc.com

Sector
Biotech
Headquarters
CAMBERWELL, VIC, C3
Founded
2010
Latest Form D
$40K, Nov 2023
Total capital
$8.1M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$8.1M
15 Form D · last Nov 2023
36 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

201220142016201820202022FEDERAL ↑EQUITY ↓Cumulative $9.6M2nd Form D$1.5M4th Form D$6.3M8th Form D$450K
201220142016201820202022FEDERAL ↑EQUITY ↓Cumulative $9.6M4th Form D$6.3M8th Form D$450K

Latest events

  • Private capital raisedForm D · SEC · 15th filing$40K
  • Private capital raisedForm D · SEC · 14th filing$61K
  • Private capital raisedForm D · SEC · 13th filing$73K
  • Private capital raisedForm D · SEC · 12th filing$55K
  • Private capital raisedForm D · SEC · 11th filing$120K
  • Private capital raisedForm D · SEC · 10th filing$65K
  • Private capital raisedForm D · SEC · 9th filing$45K
  • Private capital raisedForm D · SEC · 8th filing$450K
  • Private capital raisedForm D · SEC · 7th filing$126K
  • Private capital raisedForm D · SEC · 6th filing$105K
  • Private capital raisedForm D · SEC · 5th filing$422K
  • Private capital raisedForm D · SEC · 4th filing$6.3M
  • Private capital raisedForm D · SEC · 3rd filing$158K
  • Offering registeredForm D · SEC · 2nd filing$1.5M
  • Private capital raisedForm D · SEC · 1st filing$30K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Carlo CampicianoExecutive OfficerNamed in SEC Form D filings
  • James NathanielszExecutive Officer, DirectorNamed in SEC Form D filings
  • Josef ZelingerDirectorNamed in SEC Form D filings
  • Julian KenyonDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • AI Proteins, Inc.Similar federal contract value in Biotech · null in contracts
  • FibroGenSimilar federal contract value in Biotech · null in contracts
  • Dialectic Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • CHINA PHARMA HOLDINGS, INC.Similar federal contract value in Biotech · null in contracts
  • iToleranceSimilar federal contract value in Biotech · null in contracts
  • IZUN PHARMACEUTICALS CORPSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .